Financials in USD. Standardized financial statements.
A compact view of how GenSight Biologics S.A. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $999.63 | $1.50M | $1.27M | $2.58M | $5.28M | $4.39M | $700,000 | $4.35M | $3.70M | $3.00M |
| Revenue Growth? | -99.9% | +18.4% | -50.9% | -51.1% | +20.1% | +527.7% | -83.9% | +17.4% | +23.4% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $315,000 | $224,000 | $202,568 |
| Gross Profit? | $1,000 | $1.50M | $1.27M | $2.58M | $5.28M | $4.39M | $700,000 | $4.03M | $3.48M | $2.80M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +92.8% | +93.9% | +93.2% |
| Operating Expenses? | $11.06M | $17.31M | $30.96M | $30.42M | $33.40M | $29.33M | $31.00M | $33.05M | $23.99M | $22.02M |
| Operating Income? | -$11.70M | -$15.81M | -$29.70M | -$27.84M | -$28.13M | -$24.93M | -$30.30M | -$33.05M | -$23.99M | -$22.02M |
| EBITDA? | -$11.24M | -$11.37M | -$20.89M | -$26.77M | -$27.20M | -$24.01M | -$29.31M | -$32.73M | -$23.77M | -$24.81M |
| Income Before Tax | -$12.04M | -$13.98M | -$27.92M | -$27.62M | -$28.61M | -$34.01M | -$30.71M | -$33.45M | -$24.11M | -$22.08M |
| Income Tax Expense | $4,998 | $21,000 | -$1.70M | $5,000 | $2,000 | $2,000 | $4,000 | $0 | $2,000 | $62,977 |
| Net Income? | -$12.03M | -$14.00M | -$26.22M | -$27.62M | -$28.62M | -$34.02M | -$30.71M | -$33.45M | -$24.11M | -$22.08M |
| EPS? | $-0.08 | $-0.17 | $-0.54 | $-0.60 | $-0.63 | $-0.97 | $-1.08 | $-1.37 | $-1.10 | $-1.36 |
| Diluted EPS? | $-0.08 | $-0.17 | $-0.54 | $-0.60 | $-0.63 | $-0.97 | $-1.08 | $-1.37 | $-1.10 | $-1.36 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality